Metabotropic Glutamate Receptor 1 Expression and Its Polymorphic Variants Associate with Breast Cancer Phenotypes

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen

(2013) T Winder et al.   PHARMACOGENOMICS JOURNAL

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit

(2012) Josefine Bostner et al.   BREAST CANCER RESEARCH AND TREATMENT

Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

(2012) F. J. Couch et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium

(2012) H. Warren et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells

(2012) S. Koochekpour et al.   CLINICAL CANCER RESEARCH

11q13 is a susceptibility locus for hormone receptor positive breast cancer

(2012) Diether Lambrechts et al.   HUMAN MUTATION

Functional Effects of GRM1 Suppression in Human Melanoma Cells

(2012) J. Wangari-Talbot et al.   MOLECULAR CANCER RESEARCH

Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells

(2012) J J Martino et al.   ONCOGENE

Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer

(2011) Cecilia L. Speyer et al.   BREAST CANCER RESEARCH AND TREATMENT

Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor-Positive, Lower Grade Breast Cancer

(2011) R. L. Milne et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer

(2011) K. N. Stevens et al.   CANCER RESEARCH

Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies

(2011) H. J. Lee et al.   CLINICAL CANCER RESEARCH

Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium†

(2011) Jonine D. Figueroa et al.   HUMAN MOLECULAR GENETICS

A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer

(2011) Christopher A Haiman et al.   NATURE GENETICS

'Hide-then-hit' to explain the importance of genotypic polymorphism of DNA repair genes in determining susceptibility to cancer

(2011) P.-E. Wu et al.   Journal of Molecular Cell Biology

Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes

(2010) Madhura S. Mehta et al.   BREAST CANCER RESEARCH AND TREATMENT

Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis

(2010) Min Fang et al.   CANCER

The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment

(2010) Kelly K. Haagenson et al.   CANCER AND METASTASIS REVIEWS

Suppression of Casein Kinase 1  in Melanoma Cells Induces a Switch in  -Catenin Signaling to Promote Metastasis

(2010) T. Sinnberg et al.   CANCER RESEARCH

A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrence

(2010) Alexei Vazquez et al.   INTERNATIONAL JOURNAL OF CANCER

Evaluation of Single Nucleotide Polymorphisms (SNPs) in the p53 Binding Protein 1 (TP53BP1) Gene in Breast Cancer Patients Treated With Breast-Conserving Surgery and Whole-Breast Irradiation (BCS + RT)

(2010) Bruce G. Haffty et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

The Protective Signaling of Metabotropic Glutamate Receptor 1 Is Mediated by Sustained, β-Arrestin-1-dependent ERK Phosphorylation

(2010) Andrew C. Emery et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Glutamate Release Inhibitor Riluzole Decreases Migration, Invasion, and Proliferation of Melanoma Cells

(2010) Maithao N. Le et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population

(2010) Antonis C Antoniou et al.   NATURE GENETICS

Germline Mutations and Polymorphisms in the Origins of Cancers in Women

(2010) Kim M. Hirshfield et al.   Journal of Oncology

A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer

(2009) Diptee A. Kulkarni et al.   CARCINOGENESIS

Cancer cell lines release glutamate into the extracellular environment

(2009) Eric P. Seidlitz et al.   CLINICAL & EXPERIMENTAL METASTASIS

A Phase 0 Trial of Riluzole in Patients with Resectable Stage III and IV Melanoma

(2009) D. Yip et al.   CLINICAL CANCER RESEARCH

AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1)

(2009) Seung-Shick Shin et al.   Pigment Cell & Melanoma Research

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

(2008) Sherene Loi et al.   BMC GENOMICS

Metabotropic glutamate receptors (mGlus) and cellular transformation

(2008) Seung-Shick Shin et al.   NEUROPHARMACOLOGY

Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation

(2008) Seung-Shick Shin et al.   Pigment Cell & Melanoma Research